Paraplatin: profile and news

Herceptin® May Change the Natural History of Patients with HER2 ... May 1, 2006
...been combined with non-cardiotoxic agents such as Navelbine, Taxotere® (docetaxel), Taxol® (paclitaxel), cisplatin (Platinol®), and Paraplatin® (carboplatin ... - Cancer Consultants (press release),

Camptosar®/Carboplatin Improves Progression-Free Survival over ... Apr 21, 2006
...to an article published in the Annals of Oncology, the chemotherapy combination consisting of Camptosar® (irinotecan) plus Paraplatin® (carboplatin) appears ... - Cancer Consultants (press release),

Other information

Indication
For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide.

Pharmacology
Carboplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

Mechanism Of Action
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

Drug Category
Antineoplastic Agents; ATC:L01XA02

Brand Names/Synonyms
Cbdca; Carboplatin (USAN); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicarboxylato)diammine-, cis-; Platinum, {diammine[1,1-cyclobutanedicarboxylato(2-)-O,O']-,} (SP-4-2)-; Platinum, diamine(1, 1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-; Paraplatin; Paraplatin-AQ

Dosage Forms
SOLUTION

Absorption
Not Available

Interactions
Interactions for Carboplatin: The renal effects of nephrotoxic compounds may be potentiated by Carboplatin.

Chemical IUPAC Name
platinum;cyclobutane-1,1-dicarboxylicacid;azanide

Chemical Formula
C6H12N2O4Pt2

Half Life
1.1-2 hours

Drug Type
Approved Drug

# Accession No
APRD00466

CAS Registry Number
41575-94-4